-+ 0.00%
-+ 0.00%
-+ 0.00%

B of A Securities Maintains Neutral on Biogen, Lowers Price Target to $215

Benzinga·07/21/2026 12:34:14
Listen to the news
B of A Securities analyst Jason Zemansky maintains Biogen (NASDAQ:BIIB) with a Neutral and lowers the price target from $217 to $215.